Tearsheet
MGTX Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About MGTX Interactive Breakdown Better Bets vs. MGTX Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

MeiraGTx (MGTX)

Market Price (3/15/2026): $7.38 | Market Cap: $597.4 Mil
Sector: Health Care | Industry: Biotechnology

MeiraGTx (MGTX)

Market Price (3/15/2026): $7.38
Market Cap: $597.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 97%		 Weak multi-year price returns
2Y Excs Rtn is -16%, 3Y Excs Rtn is -71%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -164 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -598%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.		  Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -96%
2   Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 83%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -424%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -441%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32%
5   Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.64
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 97%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -16%, 3Y Excs Rtn is -71%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -164 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -598%
4 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -96%
5 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 83%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -424%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -441%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32%
8 Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.64

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

MeiraGTx (MGTX) stock has lost about 10% since 11/30/2025 because of the following key factors:

1. MeiraGTx significantly missed Q3 2025 earnings and revenue estimates, setting a negative tone for the period.

The company reported a Q3 2025 EPS of -$0.62 on November 13, 2025, missing analysts' consensus estimates of -$0.50 per share by $0.12. Additionally, quarterly revenue came in at a mere $0.41 million, substantially below analyst expectations of $7.71 million.

2. Analysts issued downgrades and maintained a negative outlook for MeiraGTx's future financial performance.

Zacks Research downgraded MeiraGTx from a "hold" to a "strong sell" rating on January 30, 2026. This followed Weiss Ratings reiterating a "sell (d-)" rating on January 22, 2026. The consensus revenue estimates for MeiraGTx also fell by 64% by November 19, 2025, with forecasts indicating the company is expected to remain unprofitable over the next three years.

Show more

Stock Movement Drivers

Fundamental Drivers

The -11.0% change in MGTX stock from 11/30/2025 to 3/13/2026 was primarily driven by a -11.0% change in the company's P/S Multiple.
(LTM values as of)113020253132026Change
Stock Price ($)8.307.39-11.0%
Change Contribution By: 
Total Revenues ($ Mil)27270.0%
P/S Multiple24.521.8-11.0%
Shares Outstanding (Mil)81810.0%
Cumulative Contribution-11.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/13/2026
ReturnCorrelation
MGTX-11.0% 
Market (SPY)-3.1%36.1%
Sector (XLV)-5.0%29.0%

Fundamental Drivers

The 1.2% change in MGTX stock from 8/31/2025 to 3/13/2026 was primarily driven by a 40.6% change in the company's P/S Multiple.
(LTM values as of)83120253132026Change
Stock Price ($)7.307.391.2%
Change Contribution By: 
Total Revenues ($ Mil)3827-27.7%
P/S Multiple15.521.840.6%
Shares Outstanding (Mil)8181-0.4%
Cumulative Contribution1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/13/2026
ReturnCorrelation
MGTX1.2% 
Market (SPY)3.0%40.1%
Sector (XLV)9.5%25.5%

Fundamental Drivers

The 3.6% change in MGTX stock from 2/28/2025 to 3/13/2026 was primarily driven by a 96.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)22820253132026Change
Stock Price ($)7.137.393.6%
Change Contribution By: 
Total Revenues ($ Mil)142796.8%
P/S Multiple36.721.8-40.5%
Shares Outstanding (Mil)7281-11.5%
Cumulative Contribution3.6%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/13/2026
ReturnCorrelation
MGTX3.6% 
Market (SPY)12.4%28.1%
Sector (XLV)1.9%29.0%

Fundamental Drivers

The -4.3% change in MGTX stock from 2/28/2023 to 3/13/2026 was primarily driven by a -44.8% change in the company's Shares Outstanding (Mil).
(LTM values as of)22820233132026Change
Stock Price ($)7.727.39-4.3%
Change Contribution By: 
Total Revenues ($ Mil)4227-35.1%
P/S Multiple8.221.8167.2%
Shares Outstanding (Mil)4581-44.8%
Cumulative Contribution-4.3%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/13/2026
ReturnCorrelation
MGTX-4.3% 
Market (SPY)73.4%28.6%
Sector (XLV)23.3%28.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MGTX Return57%-73%8%-13%31%-2%-48%
Peers Return7%-2%-5%-25%-3%0%-27%
S&P 500 Return27%-19%24%23%16%-1%80%

Monthly Win Rates [3]
MGTX Win Rate50%33%42%50%58%33% 
Peers Win Rate45%55%47%43%53%47% 
S&P 500 Win Rate75%42%67%75%67%33% 

Max Drawdowns [4]
MGTX Max Drawdown-23%-76%-45%-45%-24%-12% 
Peers Max Drawdown-31%-32%-31%-33%-40%-17% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-2% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: RGNX, SRPT, BMRN, VRTX, NTLA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)

How Low Can It Go

Unique KeyEventMGTXS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-84.8%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven559.4%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-56.2%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven128.1%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven585 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-53.6%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven115.7%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days

Compare to RGNX, SRPT, BMRN, VRTX, NTLA

In The Past

MeiraGTx's stock fell -84.8% during the 2022 Inflation Shock from a high on 12/31/2021. A -84.8% loss requires a 559.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About MeiraGTx (MGTX)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

AI Analysis | Feedback

1. A clinical-stage **Sarepta Therapeutics**, but focusing on gene therapies for inherited blindness and neurological diseases.

2. An early-stage **Vertex Pharmaceuticals**, dedicated to developing gene therapies for serious eye and brain disorders.

AI Analysis | Feedback

  • Gene Therapies for Achromatopsia: Treatments targeting Achromatopsia, a form of inherited blindness, currently in Phase 1/2 clinical development.
  • Gene Therapies for X-Linked Retinitis Pigmentosa: Treatments for X-Linked Retinitis Pigmentosa, an inherited retinal disease, currently in Phase 1/2 clinical development.
  • Gene Therapies for RPE65-deficiency: Treatments targeting RPE65-deficiency, a cause of inherited retinal degeneration, currently in Phase 1/2 clinical development.
  • Gene Therapies for Radiation-Induced Xerostomia: Treatments designed to address severe dry mouth following radiation treatment for head and neck cancers, currently in Phase 1/2 clinical development.
  • Gene Therapies for Parkinson's Disease: Treatments in development for Parkinson's disease, a neurodegenerative disorder.
  • Gene Therapies for Xerostomia related to Sjogren's Syndrome: Treatments in the early stages of clinical program initiation for dry mouth associated with Sjogren's syndrome.

AI Analysis | Feedback

MeiraGTx (MGTX) is a clinical-stage gene therapy company. At this stage, it does not sell commercial products directly to individuals or healthcare providers. Instead, its primary financial relationships involve collaborations with larger pharmaceutical companies for research and development.

Based on the provided information, MeiraGTx's major customer/partner is:

  • Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson, symbol: JNJ)

This relationship is described as a research collaboration agreement to develop regulatable gene therapy treatment.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

Better Bets vs. MeiraGTx (MGTX)

Latest Trefis Analyses

Title
0ARTICLES

Trade Ideas

Select ideas related to MGTX.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K02282026QDELQuidelOrthoInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		0.0%0.0%0.0%
CHE_2272026_Dip_Buyer_FCFYield02272026CHEChemedDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper02272026LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.0%0.0%0.0%
HAE_2202026_Dip_Buyer_FCFYield02202026HAEHaemoneticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		3.5%3.5%0.0%
IQV_2132026_Dip_Buyer_ValueBuy02132026IQVIQVIADip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		7.1%7.1%-3.0%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

MGTXRGNXSRPTBMRNVRTXNTLAMedian
NameMeiraGTx RegenxbioSarepta .BioMarin.Vertex P.Intellia. 
Mkt Price7.398.5716.4058.51469.3412.7614.58
Mkt Cap0.60.41.711.2119.01.51.6
Rev LTM271702,1983,22112,001681,184
Op Inc LTM-164-161-6584094,554-441-163
FCF LTM-121-126-3157173,194-396-124
FCF 3Y Avg-119-177-4194151,832-386-148
CFO LTM-116-124-2058283,631-395-120
CFO 3Y Avg-106-172-3045202,225-379-139

Growth & Margins

MGTXRGNXSRPTBMRNVRTXNTLAMedian
NameMeiraGTx RegenxbioSarepta .BioMarin.Vertex P.Intellia. 
Rev Chg LTM96.8%104.5%15.6%12.9%8.9%16.9%16.2%
Rev Chg 3Y Avg40.3%25.6%33.9%15.4%10.4%15.4%20.5%
Rev Chg Q-96.2%43.0%-32.7%17.0%9.5%78.8%13.3%
QoQ Delta Rev Chg LTM-27.7%5.7%-8.9%4.1%2.4%17.6%3.2%
Op Mgn LTM-597.9%-94.6%-29.9%12.7%37.9%-651.7%-62.2%
Op Mgn 3Y Avg-1,291.2%-223.1%-13.3%12.9%24.7%-998.4%-118.2%
QoQ Delta Op Mgn LTM-181.4%1.5%-26.4%-7.2%38.7%180.5%-2.9%
CFO/Rev LTM-424.1%-72.7%-9.3%25.7%30.3%-583.3%-41.0%
CFO/Rev 3Y Avg-904.2%-174.2%-20.2%17.5%20.5%-757.5%-97.2%
FCF/Rev LTM-441.5%-74.1%-14.3%22.3%26.6%-585.0%-44.2%
FCF/Rev 3Y Avg-1,053.9%-179.3%-26.7%13.7%17.0%-774.2%-103.0%

Valuation

MGTXRGNXSRPTBMRNVRTXNTLAMedian
NameMeiraGTx RegenxbioSarepta .BioMarin.Vertex P.Intellia. 
Mkt Cap0.60.41.711.2119.01.51.6
P/S21.82.60.83.59.921.96.7
P/EBIT-3.8-3.0-2.622.825.6-3.4-2.8
P/E-3.5-2.3-2.432.230.1-3.6-2.3
P/CFO-5.1-3.6-8.413.632.8-3.7-3.7
Total Yield-28.2%-43.7%-41.5%3.1%3.3%-27.9%-28.0%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-24.7%-30.2%-7.6%3.5%1.7%-27.5%-16.2%
D/E0.10.20.60.10.00.10.1
Net D/E0.1-0.40.1-0.1-0.0-0.2-0.1

Returns

MGTXRGNXSRPTBMRNVRTXNTLAMedian
NameMeiraGTx RegenxbioSarepta .BioMarin.Vertex P.Intellia. 
1M Rtn-0.9%0.8%-8.7%-3.0%1.8%6.3%-0.1%
3M Rtn-17.2%-38.2%-23.8%9.8%3.8%41.5%-6.7%
6M Rtn-2.9%-6.8%-5.7%8.2%19.0%11.7%2.6%
12M Rtn-10.4%30.8%-83.3%-17.1%-6.7%38.4%-8.6%
3Y Rtn18.2%-59.2%-88.7%-35.2%59.0%-68.2%-47.2%
1M Excs Rtn1.4%3.2%-6.3%-0.6%4.1%8.7%2.3%
3M Excs Rtn-10.3%-32.8%-24.5%10.6%7.2%37.8%-1.6%
6M Excs Rtn-6.5%-12.6%-11.3%1.8%15.3%8.9%-2.4%
12M Excs Rtn-5.7%7.5%-104.6%-38.1%-26.3%11.6%-16.0%
3Y Excs Rtn-71.1%-132.4%-159.0%-107.7%-5.2%-138.0%-120.1%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20242023202220212020
Development and manufacturing of genetic medicines1416381613
Total1416381613


Net Income by Segment
$ Mil20242023202220212020
Development and manufacturing of genetic medicines-84    
Total-84    


Price Behavior

Price Behavior
Market Price$7.39 
Market Cap ($ Bil)0.6 
First Trading Date06/08/2018 
Distance from 52W High-20.2% 
   50 Days200 Days
DMA Price$7.59$7.74
DMA Trendupdown
Distance from DMA-2.6%-4.5%
 3M1YR
Volatility49.1%60.9%
Downside Capture245.42211.27
Upside Capture171.19159.14
Correlation (SPY)36.0%26.9%
MGTX Betas & Captures as of 2/28/2026

 1M2M3M6M1Y3Y
Beta1.791.461.601.860.971.30
Up Beta0.892.170.921.220.430.87
Down Beta1.190.17-0.052.331.021.12
Up Capture236%183%244%194%183%384%
Bmk +ve Days9203170142431
Stock +ve Days10202961122356
Down Capture211%190%252%169%131%111%
Bmk -ve Days12213054109320
Stock -ve Days11213262125380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MGTX
MGTX3.1%66.3%0.30-
Sector ETF (XLV)5.0%17.5%0.1231.8%
Equity (SPY)19.6%18.9%0.8128.2%
Gold (GLD)71.9%26.3%2.051.0%
Commodities (DBC)19.3%17.3%0.894.3%
Real Estate (VNQ)6.2%16.3%0.1918.1%
Bitcoin (BTCUSD)-15.3%44.2%-0.2522.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MGTX
MGTX-14.6%65.4%0.02-
Sector ETF (XLV)7.5%14.5%0.3328.5%
Equity (SPY)13.1%17.0%0.6131.6%
Gold (GLD)24.1%17.3%1.144.2%
Commodities (DBC)11.2%19.0%0.473.5%
Real Estate (VNQ)4.8%18.8%0.1628.9%
Bitcoin (BTCUSD)6.3%56.7%0.3317.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MGTX
MGTX-7.9%66.6%0.12-
Sector ETF (XLV)10.1%16.5%0.5033.6%
Equity (SPY)14.5%17.9%0.7036.3%
Gold (GLD)14.4%15.6%0.773.7%
Commodities (DBC)8.6%17.6%0.4010.0%
Real Estate (VNQ)5.6%20.7%0.2333.1%
Bitcoin (BTCUSD)67.4%66.8%1.0717.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date2272026
Short Interest: Shares Quantity5.1 Mil
Short Interest: % Change Since 2152026-2.2%
Average Daily Volume0.3 Mil
Days-to-Cover Short Interest19.6 days
Basic Shares Quantity80.9 Mil
Short % of Basic Shares6.3%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/13/2025-4.6%-12.5%2.8%
8/14/2025-0.1%-9.4%-8.8%
3/13/202528.7%21.2%-20.9%
11/13/20245.7%-10.2%-9.8%
8/12/2024-8.5%-3.2%-6.9%
3/14/2024-7.1%2.2%-12.4%
11/14/20232.3%19.7%0.8%
8/10/20234.3%1.4%-3.8%
...
SUMMARY STATS   
# Positive973
# Negative91115
Median Positive4.3%8.4%2.0%
Median Negative-4.6%-9.4%-8.8%
Max Positive28.7%21.2%2.8%
Max Negative-14.0%-33.0%-20.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202505/13/202510-Q
12/31/202403/13/202510-K
09/30/202411/13/202410-Q
06/30/202408/12/202410-Q
03/31/202405/09/202410-Q
12/31/202303/15/202410-K
09/30/202311/14/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/14/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
03/31/202205/12/202210-Q
12/31/202103/10/202210-K

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Giroux, RichardCFO & COODirectSell102120258.8724,000212,8807,357,612Form
2Forbes, AlexandriaPRESIDENT & CEODirectSell100720258.3947,500398,52511,024,317Form
3Giroux, RichardCFO & COODirectSell72220258.5224,000204,4807,271,769Form
4Forbes, AlexandriaPRESIDENT & CEODirectSell70820257.9747,500378,57510,851,020Form
5Giroux, RichardCFO & COODirectSell42220256.0024,000144,0005,294,964Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.